MMI 0100 - Moerae Matrix

Drug Profile

MMI 0100 - Moerae Matrix

Alternative Names: MMI-0100

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Moerae Matrix
  • Class Anti-inflammatories; Antifibrotics; Peptides
  • Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis
  • No development reported Fibrosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA
  • 28 Jul 2015 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top